T. Rowe Price Investment Management, Inc. Fate Therapeutics Inc Transaction History

T. Rowe Price Investment Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $23,124 - $32,014	4,858 Added 4.85%	104,938 $500,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $1.42 Million - $3.71 Million	-333,789 Reduced 76.93%	100,080 $571,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $273,368 - $660,686	27,725 Added 6.83%	433,869 $4.38 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $8.55 Million - $14.6 Million	406,144 New	406,144 $9.1 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.